Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.41 |
| ▸ | FEN1 | P39748 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17310247 | 0.89 | ZAP70 (0.46) | PIK3CAALKEGFRATR | |
| SCHEMBL17310205 | 0.81 | ALK (0.44) | PIK3CAALKEGFRBRD4 | |
| SCHEMBL17310235 | 0.73 | ALK (0.72) | ALK | |
| SCHEMBL17310117 | 0.72 | ALK (0.75) | ALK | |
| SCHEMBL3622493 | 0.72 | PDK2 (0.50) | PIK3CAALKPDK2ATRSMARCA2 | |
| SCHEMBL25192257 | 0.71 | ALK (0.50) | PIK3CAALKSMARCA2SMARCA4PBRM1 | |
| SCHEMBL31173935 | 0.71 | ALK (0.50) | PIK3CAALKSMARCA2SMARCA4PBRM1 | |
| SCHEMBL30796360 | 0.71 | SMARCA2 (0.58) | PIK3CAALKPDK2ATRSMARCA2 | |
| SCHEMBL19139192 | 0.70 | PIK3CA (0.44) | PIK3CAALKPDK2SMARCA2SMARCA4 | |
| SCHEMBL24590335 | 0.70 | ALK (0.57) | ALKEGFRPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708295-B2 | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-07-18 | — | — | US | disclosed |
| US-9708295-B2 | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-07-18 | — | — | US | disclosed |
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | PACSIN2, MAPKAPK2, PRKCA | PIK3CA 266/4885ALK 853/4885EGFR 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.